ArticlePloS one2025
Transcriptomic and experimental evidence confirm the potential of disulfidptosis-related signature for the early diagnosis and treatment of liver cirrhosis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Disulfidptosis in hepatocellular carcinoma: molecular mechanisms, therapeutic potential, and exploratory insights into chronic liver diseases.Apoptosis : an international journal on programmed cell death · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cirrhosis is a common endpoint in various chronic liver diseases, and often causes hepatocellular carcinoma. Studies have revealed the significant role of disulfidptosis in the occurrence and development of hepatocellular carcinoma; however, our understanding of this role is limited. Therefore, we aimed to identify potential disulfidptosis-related biomarkers for cirrhosis. We obtained the gene expression data of patients with cirrhosis from the Gene Expression Omnibus (GEO) database. Subsequently, weighted gene co-expression network analysis was performed, and the "limma" package was used to screen for differentially expressed genes (DEGs) associated with disulfidptosis. Significantly altered biological pathways were identified using Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Set Enrichment Analysis (GSEA), and Gene Set Variation Analysis (GSVA). We constructed protein-protein interaction (PPI) networks using GeneMANIA and generated receiver operating characteristic (ROC) curves to identify hub-shared genes. Additionally, we assessed the distribution of immune cell populations in cirrhotic and control specimens using single-sample GSEA (ssGSEA) and explored their relationship with hub genes. Six hub genes (CXCL12, COL1A1, CXCR4, COL1A2, CCR7, and CXCL8) were closely associated with disulfidptosis-related DEGs. Further immunohistochemical experiments confirmed the potential of CCR7, CXCL12, CXCR4, and CXCL8 as novel diagnostic biomarkers and suggested their potential as new therapeutic targets. These genes mainly promote the development of liver cirrhosis through the oxidative metabolism and cytokine pathways. Furthermore, we observed positive correlations among 23 of the 28 types of immune cells. This study highlights the potential utility of immune cell infiltration and efficient disulfidptosis-related early diagnostic biomarkers in cirrhosis, and highlights its strong useful as a therapeutic target, offering potential clinical application value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.